Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Glucose Monitoring, Other

Diabetes Research Institute Appoints Matthias von Herrath as Scientific Director; Nemaura Receives First proBEAT Purchase Order from HealthFleet

Here is a brief preview of this blast: Two cardiometablic-related news items have been observed: The Diabetes Research Institute announced the appointment of its new scientific director, Matthias von Herrath (view press release; LinkedIn); and Nemaura Medical announced it has received an initial purchase order for 5,000 proBEAT subscriptions from HealthFleet Inc. (view press release). Below, FENIX provides highlights and insights including commentary on Matthias von Herrath’s potential impact on the DRI’s T1DM mission in the context of his current role as VP and Senior Medical Officer for Novo Nordisk.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.